India, May 21 -- HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company developing fusion Immunotherapeutics for cancer, autoimmune disease, and age-related disorders, announced the pricing of a private placement valued at approximately $4.0 million.
Offering Details
The financing involves 2,846,975 units priced at $1.405 per unit, each consisting of one share of common stock (or a pre-funded warrant) and one warrant to purchase common stock. The warrant are exercisable immediately at $1.28 per share and will expire five and a half years from issuance.
The closing of the offering is expected on or about May 21, 2025, subjected to customary closing conditions. E.F. Hutton & Co. LLC is acting as the sole placement agent.
Us...